SFRT delivers high doses of radiation without exceeding the tolerance of critical structures, particularly skin, by limiting the volume of irradiated tissue. Early-phase clinical studies show excellent response rates, often with dramatic and rapid resolution of large tumors.
Technological advancements continue to expand its use into unique and more reproducible formats. Radiobiological experiments support the role of radiation-induced bystander
effects, vascular alterations, and immunologic interactions. However, further preclinical data are necessary to determine optimal SFRT planning, and clinical trials need to clearly define the role of SFRT in the clinical setting. The dissemination of the new evidence generated by leading institutions and cooperative groups is needed to benefit entire groups of patients. To achieve this benefit at a population level, it is critical to maximize the impact of SFRT through an adequate implementation of this technique in countries or regions where advanced, bulky tumors are a common oncology problem and can benefit the most.
In the context of cervical cancer and lung cancer this may cause a more cost-effective use of the resources, and a better access to treatment for the population.
In this CRP, we propose to:
Use SFRT to stimulate an immunogenic response to palliative radiotherapy, which delays progression of disease at any site, in patients with locally advanced or metastatic NSCLC and Cervical Carcinoma.

 
The idea for this CRP originates from:
Review of the relevant scientific literature

Consultancy meeting with experts